Trial · NCT06516965
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965, Phase 3, Active not recruiting, Incyte Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2). Trials, record NCT06516965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06516965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- NCT number
- NCT06516965
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 346 participants, actual
- Lead sponsor
- Incyte Corporation
- Conditions
- Prurigo Nodularis
- Interventions
- Povorcitinib, Placebo
- First posted
- 2024-07-24
- Last updated
- 2026-04-14
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24 | Week 24 | Defined as proportion of participants achieving a ≥ 4-point improvement \[reduction\] in Itch NRS score from baseline (Itch NRS4) and an IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline (IGA-CPG-S-TS). |
| Secondary | Proportion of participants achieving Itch NRS4 at Week 24 | Week 24 | Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
| Secondary | Proportion of participants achieving IGA-CPG-S-TS at Week 24 | Week 24 | Defined as percentage of participants that achieve IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
| Secondary | Proportion of participants achieving Itch NRS4 at Week 4 | Week 4 | Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline. |
| Secondary | Time to Itch NRS4 | Up to 52 Weeks | Defined as time taken for the participant to achieve a ≥4 improvement in Itch NRS score from baseline. |
| Secondary | Change from baseline in Itch NRS score at each postbaseline visit | Up to 52 weeks | Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
| Secondary | Percent change from baseline in NRS score at each postbaseline visit | Up to 52 weeks | Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable". |
| Secondary | Proportion of participants achieving Itch NRS4 at each postbaseline visit | Up to 52 weeks | Defined as percentage of participants that achieve a ≥ 4-point improvement in Itch NRS score from baseline. |
| Secondary | Proportion of participants achieving IGA-CPG-S-TS at each postbaseline visit | Up to 52 weeks | Defined as percentage of participants that achieve an IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline. |
| Secondary | Proportion of participants achieving Investigator's Global Assessment - Chronic Prurigo Activity (IGA-CPG-A) at each postbaseline visit | Up to 52 weeks | Defined as percentage of participants that achieve an IGA-CPG-A score of 0 or 1 with a ≥ 2 grade improvement (reduction) from baseline. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06516965
GET https://conductscience.org/api/trials/v1/NCT06516965/registered?page=2